Full history for every metric is available with a Kvantra account
CymaBay Therapeutics, Inc. (CBAY)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 31 | 31 |
| Operating profit | $m | -102 | -102 | |||||
| Net profit | $m | -73 | -102 | -49 | -93 | -119 | -105 | -112 |
| EPS reported | $ | -0.99 | -1.06 | |||||
| Operating cashflow per share | $ | -0.68 | -0.68 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.69 | -0.69 | |||||
| Free cash flow | $m | -73 | -73 | |||||
| Net debt | $m | -280 | -285 | |||||
| Book value equity | $m | 292 | 292 | |||||
| Book value per share | $ | 2.75 | 2.58 | |||||
| Number of shares | m | 106.2 | 113.32 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.58 | 12.76 | |||||
| P/S LTM | x | 80.73 | 119.98 | |||||
| P/FCF LTM | x | -34.37 | -51.09 | |||||
| EV/EBITDA LTM | x | -28.18 | -36.08 | |||||
| EV/Sales LTM | x | 77.77 | 110.81 | |||||
| Earnings Yield LTM | % | -4.20% | -3.05% | |||||
| FCF Yield | % | -2.91% | -1.96% | |||||
| Quality | ||||||||
| ROE | % | -36.05% | -64.17% | |||||
| ROIC | % | -24.93% | -24.93% | |||||
| Operating margin | % | -327.23% | -327.23% | |||||
| Gross margin | % | 97.81% | 97.81% | |||||
| FCF/Sales | % | -234.85% | -234.85% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.64 | -0.64 | |||||
| Net Debt/EBITDA | x | 1.07 | 1.07 | |||||
| EBIT/Net interest | x | -5.37 | -5.37 | |||||
| Net debt/market cap | % | -11.15% | -7.65% | |||||
| Net debt/Equity | x | -0.96 | -0.98 | |||||
| Gross debt/equity | x | 0.39 | 0.39 | |||||
Company overview
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CymaBay Therapeutics, Inc. (CBAY)
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free